CancerDrs

Colorectal Cancer clinical trials in Nebraska

21 actively recruiting colorectal cancer trials at 8 sites across Nebraska.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Nebraska:
  • Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
  • Cancer Partners of Nebraska — Lincoln, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Nebraska:
  • CHI Health Saint Francis — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
  • Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
  • Alegent Health Lakeside Hospital — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …

Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Nebraska:
  • Cancer Partners of Nebraska — Lincoln, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…

Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Nebraska:
  • Clinical Study Site — Lincoln, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in Nebraska:
  • Nebraska Cancer Specialists Midwest Cancer Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…

Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in Nebraska:
  • GSK Investigational Site — Grand Island, Nebraska
  • GSK Investigational Site — Omaha, Nebraska
  • GSK Investigational Site — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Nebraska:
  • University Of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Nebraska:
  • University Of Nebraska Medical Center ( Site 0078) — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Nebraska:
  • Nebraska Cancer Specialists — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Nebraska:
  • Nebraska Cancer Specialists — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Nebraska:
  • Exelixis Clinical Site #2 — Omaha, Nebraska
  • Exelixis Clinical Site #5 — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Nebraska:
  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399 — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …

Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Nebraska:
  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy) — Omaha, Nebraska
  • XCancer Omaha / Urology Cancer Center — Omaha, Nebraska
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.

Sponsor: NRG Oncology
NCT ID: NCT05080673
Sites in Nebraska:
  • CHI Health Saint Francis — Grand Island, Nebraska
  • Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Nebraska:
  • CHI Health Saint Francis — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
  • Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
  • Alegent Health Lakeside Hospital — Omaha, Nebraska
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Nebraska:
  • Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
  • Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Nebraska:
  • Massive Bio SYNERGY-AI site — Omaha, Nebraska
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Nebraska:
  • Mary Lanning Healthcare, Morrison Cancer Center — Hastings, Nebraska
  • Faith Regional Health Services, Carson Cancer Center — Norfolk, Nebraska
  • Great Plains Regional Medical Center — North Platte, Nebraska
  • Methodist Estabrook Cancer Center — Omaha, Nebraska
  • Nebraska Methodist Health System — Omaha, Nebraska
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans

African Americans face racial disparities in colorectal cancer (CRC), with lower screening rates and higher incidence and mortality rates. To address this gap and improve CRC screening rates, investigators aims to recruit a total of 1,200 …

Sponsor: University of Nebraska
NCT ID: NCT05903885
Sites in Nebraska:
  • Department of Motor Vehicles (DMV) — Omaha, Nebraska
  • Douglas County Treasurer's Office — Omaha, Nebraska
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10